Third-Line Treatments in Metastatic Colorectal Cancer
Expert Review
Expert Review

Third-Line Treatments in Metastatic Colorectal Cancer

What Every Nurse Needs to Know About Managing Adverse Events

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Activity Overview

This highly engaging, mixed-media, educational activity is designed specifically to address the needs of nurses who manage patients with metastatic colorectal cancer. Hear from the experts as they discuss safety issues related to third-line treatments and review optimal communication strategies for educating patients about treatment-related adverse events (TEAEs). These communication techniques are then modeled in an animated, role-play exercise. This activity also includes interactive components and valuable downloadable tools for nurses to use with their patients and colleagues.

Interactive Presentation

Interactive Presentation

Animation

Animation

Patient Education

Patient Education

Release Date

Release Date

Aug 10, 2018

Expiration Date

Aug 10, 2019

  • Pascale Dielenseger, RNInstitut Gustave Roussy
    Villejuif, France
  • Paz Fernández Ortega, PhD, MSc, RN, BPsychHospital Duran i Reynals
    Barcelona, Spain
  • Epidemiology of metastatic colorectal cancer and current medical therapies in the first-, second-, and third-line settings
  • Safety issues with third-line treatment options and how they are managed
  • Best practices for communicating with patients about medication side effects

This educational activity is designed for registered nurses and advanced-practice registered nurses who are active in the treatment/management of patients with colorectal cancer.

After successful completion of this educational activity, participants should be able to:

  • Analyze the available agents used in the third-line treatment of metastatic colorectal cancer
  • Assess common TEAEs associated with agents used in the third-line treatment of metastatic colorectal cancer
  • Describe best practices that can foster improved nurse-patient discussions/communication that can address, educate on, and manage potential TEAEs associated with third-line treatments for metastatic colorectal cancer

Accéder à l’activité en français

Se voulant avant tout stimulante, cette activité pédagogique multisupport est conçue pour répondre aux attentes du personnel infirmier ayant à charge des patients souffrant d’un cancer colorectal métastatique (CCRm). Écoutez ce que d’éminents spécialistes ont à dire sur les questions liées à l’innocuité dans les traitements de troisième intention, et familiarisez-vous avec plusieurs stratégies de communication visant à éduquer les patients sur les événements indésirables associés aux soins (EIAS). Ces techniques de communication sont ensuite mises à l’épreuve lors d’un jeu de rôle. Cette activité comprend également des éléments interactifs ainsi que divers outils pratiques que le personnel infirmier pourra télécharger afin de les utiliser avec leurs patients et collègues.

Aktivität auf Deutsch ansehen

Diese hoch-attraktive Weiterbildungsaktivität mit verschiedenen Medien wurde speziell für Krankenschwestern konzipiert, die Patienten mit metastasiertem kolorektalem Karzinom betreuen. Hören Sie Meinungen von Experten zu Sicherheitsaspekten bei Drittlinientherapien und zu optimalen Kommunikationsstrategien bei der Aufklärung von Patienten über behandlungsbedingte Nebenwirkungen. Diese Kommunikationstechniken werden in einem animierten Rollenspiel modelliert. Diese Aktivität umfasst auch interaktive Komponenten und wertvolle Ressourcen, die die Krankenschwestern herunterladen und für ihre Patienten und Kollegen verwenden können.

Visualizza l’attività in italiano

Questa stimolante attività formativa multimediale è pensata per rispondere alle esigenze specifiche del personale infermieristico che gestisce pazienti affetti da cancro del colon-retto metastatico (mCCR). Comprende una discussione sulla sicurezza dei trattamenti di terza linea e una revisione delle strategie comunicative ottimali per informare i pazienti circa gli eventi avversi delle terapie (treatment-related adverse events, TEAE). Queste tecniche di comunicazione sono poi inserite in un gioco di ruolo animato. Questa attività include anche degli elementi interattivi e utili strumenti scaricabili che il personale infermieristico potrà utilizzare con pazienti e colleghi.

Ver Actividad en español

Esta interesante actividad formativa multimedia está diseñada específicamente para abordar las necesidades de los/las enfermeros/as que tratan a pacientes de cáncer colorrectal metastásico (CCRm). Los especialistas analizarán los problemas de seguridad relacionados con los tratamientos de tercera línea y revisarán las estrategias de comunicación óptimas para educar a los pacientes sobre los acontecimientos adversos relacionados con el tratamiento (AART). Esas técnicas de comunicación se mostrarán después en un ejercicio de dramatización en vídeo. En la actividad también se incluyen componentes interactivos y útiles herramientas descargables que los/las enfermeros/as podrán utilizar con sus pacientes y compañeros de trabajo.

This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals, Inc.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

The European Oncology Nursing Society (EONS) has agreed to endorse this educational activity, Third-Line Treatments in Metastatic Colorectal Cancer: What Every Nurse Needs to Know About Managing Adverse Events. This endorsement states that EONS supports the intended aims of this Continuing Education Programme.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Pascale Dielenseger has disclosed that she is on a European nursing advisory board for Bayer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Paz Fernández Ortega has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Kristin Tomlinson, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.